Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | Pyruvate kinase homolog | 0.0034 | 0.2059 | 1 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.0034 | 0.2059 | 1 |
Loa Loa (eye worm) | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Plasmodium falciparum | pyruvate kinase | 0.0034 | 0.2059 | 1 |
Leishmania major | pyruvate kinase | 0.0034 | 0.2059 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0125 | 1 | 1 |
Brugia malayi | Pyruvate kinase, muscle isozyme | 0.0034 | 0.2059 | 0.2059 |
Schistosoma mansoni | pyruvate kinase | 0.0017 | 0.0643 | 0.0643 |
Mycobacterium tuberculosis | Probable pyruvate kinase PykA | 0.0034 | 0.2059 | 0.5 |
Mycobacterium ulcerans | pyruvate kinase | 0.0034 | 0.2059 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0125 | 1 | 1 |
Echinococcus multilocularis | pyruvate kinase | 0.0017 | 0.0643 | 0.0643 |
Echinococcus granulosus | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Loa Loa (eye worm) | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Giardia lamblia | Pyruvate kinase | 0.0034 | 0.2059 | 1 |
Brugia malayi | Pyruvate kinase, M2 isozyme | 0.0034 | 0.2059 | 0.2059 |
Chlamydia trachomatis | pyruvate kinase | 0.0034 | 0.2059 | 0.5 |
Echinococcus granulosus | pyruvate kinase | 0.0017 | 0.0643 | 0.0643 |
Loa Loa (eye worm) | pyruvate kinase-PB | 0.0023 | 0.1179 | 0.1179 |
Echinococcus granulosus | pyruvate kinase | 0.0017 | 0.0643 | 0.0643 |
Echinococcus multilocularis | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Trypanosoma brucei | pyruvate kinase 1 | 0.0034 | 0.2059 | 0.5 |
Echinococcus multilocularis | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Brugia malayi | TAR-binding protein | 0.0125 | 1 | 1 |
Trichomonas vaginalis | pyruvate kinase, putative | 0.0034 | 0.2059 | 0.5 |
Echinococcus granulosus | pyruvate kinase | 0.0017 | 0.0643 | 0.0643 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0125 | 1 | 1 |
Echinococcus multilocularis | pyruvate kinase | 0.0017 | 0.0643 | 0.0643 |
Trichomonas vaginalis | pyruvate kinase, putative | 0.0034 | 0.2059 | 0.5 |
Schistosoma mansoni | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Onchocerca volvulus | Pyruvate kinase homolog | 0.0034 | 0.2059 | 1 |
Entamoeba histolytica | pyruvate kinase, putative | 0.0023 | 0.1179 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.2059 | 0.2059 |
Echinococcus multilocularis | pyruvate kinase | 0.0026 | 0.1446 | 0.1446 |
Echinococcus multilocularis | pyruvate kinase | 0.0017 | 0.0643 | 0.0643 |
Schistosoma mansoni | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Echinococcus multilocularis | tar DNA binding protein | 0.0125 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.1179 | 0.1179 |
Echinococcus granulosus | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0125 | 1 | 1 |
Leishmania major | pyruvate kinase | 0.0034 | 0.2059 | 0.5 |
Trypanosoma cruzi | pyruvate kinase 2, putative | 0.0034 | 0.2059 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0125 | 1 | 1 |
Loa Loa (eye worm) | pyruvate kinase | 0.0034 | 0.2059 | 0.2059 |
Toxoplasma gondii | pyruvate kinase PyK1 | 0.0034 | 0.2059 | 1 |
Brugia malayi | Pyruvate kinase, alpha/beta domain containing protein | 0.001 | 0.0031 | 0.0031 |
Mycobacterium leprae | Probable pyruvate kinase PykA | 0.0034 | 0.2059 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0125 | 1 | 1 |
Plasmodium vivax | pyruvate kinase, putative | 0.0034 | 0.2059 | 1 |
Trypanosoma cruzi | pyruvate kinase 2, putative | 0.0034 | 0.2059 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0125 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0125 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0125 | 1 | 1 |
Trypanosoma brucei | pyruvate kinase 1, putative | 0.0034 | 0.2059 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0125 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.